PRESS RELEASE published on 05/28/2026 at 19:06, 2 months 30 days ago Inside Information / Other news releases ABIONYX Pharma updates its operations and cash position for Q1 2026. Consolidated revenue of €0.8M, cash reserves of €2.8M. Funding secured till 2028 through capital increase and non-dilutive loan Revenue Cash Position Funding ABIONYX Pharma Q1 2026
PRESS RELEASE published on 05/27/2026 at 07:30, 3 months 1 day ago Inside Information / Other news releases ABIONYX Pharma launches a fully secured capital increase with preferential subscription rights and structured debt financing for up to EUR 33M. Finnja Capital commits EUR 10M in a non-dilutive loan Capital Increase Preferential Subscription Rights ABIONYX Pharma Fenja Capital Structured Debt Financing
PRESS RELEASE published on 05/27/2026 at 07:30, 3 months 1 day ago Informations privilégiées / Autres communiqués
BRIEF published on 04/08/2026 at 23:59, 4 months 19 days ago ABIONYX Reports Share Capital and Voting Rights Details Euronext Paris Share Capital Voting Rights Financial Disclosure ABIONYX
BRIEF published on 04/08/2026 at 23:59, 4 months 19 days ago ABIONYX publie des informations détaillées sur son capital social et ses droits de vote Euronext Paris Capital Social Droit De Vote Divulgation Financière ABIONYX
PRESS RELEASE published on 04/08/2026 at 23:54, 4 months 19 days ago Inside Information / Other news releases ABIONYX Pharma releases monthly statement of total voting rights and shares for March 31, 2026, in accordance with French regulations Shares French Regulations Total Voting Rights Biotech Company ABIONYX Pharma
PRESS RELEASE published on 04/08/2026 at 23:54, 4 months 19 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma communique sur le nombre total de droits de vote et d'actions en circulation, illustrant son engagement envers le développement de biomédicaments innovants pour les maladies inflammatoires les plus sévères Développement Maladies Inflammatoires Biopharma ABIONYX Pharma Biomédicaments
BRIEF published on 03/17/2026 at 19:31, 5 months 10 days ago Mise à disposition du Document d’Enregistrement Universel 2025 par ABIONYX Pharma AMF Biopharmaceutique Document D’enregistrement ABIONYX Pharma Sepsis
BRIEF published on 03/17/2026 at 19:31, 5 months 10 days ago ABIONYX Pharma makes available the 2025 Universal Registration Document AMF Biopharmaceutical Registration Document ABIONYX Pharma Sepsis
PRESS RELEASE published on 03/17/2026 at 19:26, 5 months 10 days ago Inside Information / Other news releases ABIONYX Pharma announces the availability of its Universal Registration Document for the year 2025, filed with the AMF and accessible on their website AMF Biopharmaceutical Universal Registration Document ABIONYX Pharma Sepsis
Published on 08/28/2026 at 14:00, 4 hours 34 minutes ago Lobe Sciences Expands Leadership Team with New CFO Appointment
Published on 08/28/2026 at 13:00, 5 hours 34 minutes ago Abasca Files NI 43-101 Technical Report, Commences Summer Exploration Program at Loki and Elects to File Semi-annual Interim Financial Statements and Related MD&A
Published on 08/28/2026 at 08:05, 10 hours 29 minutes ago Caledonia Mining Corporation Plc: Maiden Mineral Resource Estimate at Motapa 379,000 oz Measured and Indicated; 131,000 oz Inferred
Published on 08/28/2026 at 08:05, 10 hours 29 minutes ago Tocvan Announces New Surface Mineralization in Several Zones at Gran Pilar Gold-Silver Project
Published on 08/28/2026 at 08:00, 10 hours 34 minutes ago Caledonia Mining Corporation Plc: Blanket Mine Underground Measured and Indicated Mineral Resources Estimate Increases by 22% to 2.18 Million Ounces and Declaration of a Surface Mineral Resource Estimate
Published on 08/28/2026 at 18:01, 33 minutes ago CPI Europe announces unaudited results for the first half of 2026
Published on 08/28/2026 at 18:00, 34 minutes ago Highlight Event and Entertainment AG publishes results for the first half of 2026
Published on 08/28/2026 at 18:00, 34 minutes ago Investis successfully issues a fixed rate bond of CHF 100 million
Published on 08/28/2026 at 18:00, 34 minutes ago Investis émet avec succès un emprunt obligataire à taux fixe d’un volume de CHF 100 millions
